Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Operating Income (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Operating Income readings, the most recent being -$94535.0 for Q1 2026.

  • On a quarterly basis, Operating Income fell 2.54% to -$94535.0 in Q1 2026 year-over-year; TTM through Jan 2026 was -$640006.0, a 32.02% increase, with the full-year FY2025 number at -$637662.0, up 50.48% from a year prior.
  • Operating Income hit -$94535.0 in Q1 2026 for Pharma-Bio Serv, up from -$133272.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $460466.0 in Q3 2023 to a low of -$438300.0 in Q1 2024.
  • Median Operating Income over the past 5 years was -$92191.0 (2025), compared with a mean of $16033.6.
  • Biggest five-year swings in Operating Income: skyrocketed 103.52% in 2022 and later tumbled 233.37% in 2024.
  • Pharma-Bio Serv's Operating Income stood at $168962.0 in 2022, then plummeted by 130.64% to -$51765.0 in 2023, then tumbled by 197.75% to -$154130.0 in 2024, then grew by 13.53% to -$133272.0 in 2025, then rose by 29.07% to -$94535.0 in 2026.
  • The last three reported values for Operating Income were -$94535.0 (Q1 2026), -$133272.0 (Q4 2025), and -$313877.0 (Q3 2025) per Business Quant data.